• GP Solutions is dedicating a series of its innovative and disruptive GrowPod agricultural solutions to the cannabis market through an agreement with rapper and cannabis advocate Snoop Dogg
• The company introduced its ‘Snoop’s Premium Nutrients Pods’ to popular acclaim at the recent CannaCon South convention in Oklahoma City
• Oklahoma is a significant target market, because it has one of the most business-friendly medical marijuana licensing initiatives in the country; GP Solutions expects to open a GrowPod showroom and sales office in Tulsa this month
• The Tulsa facility will also include a training and educational center to teach students about new advances in high-tech agriculture, playing on GrowPods’ advances in cultivating clean and healthy vegetables and herbs for a variety of markets
• GP Solutions also applied for uplisting to the OTCQX Best Market during the past month in an effort to add more value to stockholders’ portfolios

Agricultural technology innovator GP Solutions (OTC: GWPD) recently signed an agreement with rapper, media personality and business builder Snoop Dogg to dedicate some of the company’s innovative and automated micro-farms to a co-branding venture with the ganjapreneur, developing a series of its trademarked GrowPods to be configured as ‘Snoop’s Premium Nutrients Pods’.

The deal is part of a venture through which GP Solutions will become a distributor of Snoop’s Premium Nutrients, a premier product line developed in Holland for the cannabis market (http://ibn.fm/pzHE5). Snoop Dogg is a longtime advocate of legal cannabis, and customers who purchase one of his branded pods will receive a six-month supply of the premium nutrients as part of each package.

GP Solutions debuted the first Snoop’s Premium Nutrients Pods at the CannaCon South convention in Oklahoma City in late September. The company’s GrowPods are designed for easy operation, streamlining the start-up process to allow users of all levels of experience to begin farming and generating revenue as rapidly as possible.

“Our Snoop’s Premium Nutrients Pods were the hit of the show,” GP Solutions CEO George Natzic stated in a news release (http://ibn.fm/MsYHh). “Not only was the interest level incredibly high, but we are also in the process of closing multitudes of deals.”

It’s been a little over a year since Oklahoma voters approved one of the most business-friendly medical marijuana initiatives in the country, granting the state its status as the only market in the United States where more grower licenses have been issued than dispensaries and processors combined, according to Marijuana Business Daily (http://ibn.fm/KMd4z).

GP Solutions announced at the beginning of September that it will open a GrowPod showroom and sales office in Tulsa, Oklahoma, in a facility that will also feature a training and educational center to teach students about new advances in high-tech agriculture and to train customers on the operation of GrowPods (http://ibn.fm/m4KkM).

The company’s Oklahoma operation, scheduled to open to the public later this month, will place it at the heart of the exploding legal cannabis industry, but also in the heartland of one of the largest agriculture markets in the world. GrowPods have previously been used to cultivate clean and healthy vegetables and herbs for a variety of markets, including restaurants, grocery, organics, farm stands and traditional farming, allowing for growth of a new category of ‘Superfoods’ that are “better than organic.”

GrowPods’ advantages include an average of eight-times more yield than other forms of agriculture, indoor cultivation that provides year-round growth and consequently greater opportunity for generating revenue, portability that allows the pods to be set up virtually anywhere, high water and power resource efficiency, and easy scalability thanks to the stackable pod design.

The pods are also pesticide-free and protected from bacteria through the utilization of sealed environments.

“The Oklahoma Center has the potential to become a tremendous growth driver for the company,” Natzic stated.

Regarding the Snoop’s Premium Nutrients Pods, he added, “This is an enormous opportunity for our company that will heighten visibility in the cannabis market and give growers a complete solution for rapid and robust cultivation. We are now positioned as the most complete turnkey system in the industry.”

The company applied to uplist to the OTCQX Best Market in September, anticipating that it will be able to provide “additional transparency with our shareholders and wider communications with the investing community” while meeting more stringent market cap and revenue requirements (http://ibn.fm/iyKwC).

For more information, visit the company’s website at www.GrowPodSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to GWPD are available in the company’s newsroom at http://ibn.fm/GWPD

• OGI recently received government approval and licensing for 17 additional cultivation rooms
• The company’s licensed production capacity now totals 76,000 kilograms per year
• Organigram’s strategic plan for continued expansion is reportedly on schedule

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), a leading Canadian licensed producer (LP) of premium-quality cannabis and extract-based products, has obtained Health Canada approval for licensing of 17 additional cultivation rooms. The move brings the company’s total target licensed production capacity to 76,000 kilograms per year (http://ibn.fm/hl2G8). This is the next step in the company’s strategic plan to increase capacity and further improve its efficiencies of scale.

The new cultivation rooms represent approximately 15,000 kilograms per year of additional production capacity and are part of Organigram’s strategic phase 4B expansion plan.

“Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date,” Organigram CEO Greg Engel stated in a news release. “Our phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale.”

As a result of the government licensing and approval, the company will immediately begin moving cannabis plants into the new rooms on a rolling basis. Organigram projects it will see the initial crop from these new rooms by the end of November 2019, assuming normal cultivation timelines. Following drying and post-harvest processing, the company anticipates having dried-flower product from these additional rooms available for sale to patients and customers in its fiscal quarter ending February 2020.

Additional construction outlined in phase 4B of the company’s expansion plans is on schedule to be completed later this month. The company plans on submitting the licensing amendment for its remaining 16 phase 4B cultivation rooms this month, as well. The perimeter of phase 5 of the company’s expansion, which will include an edibles and derivative product facility and more extraction capacity, is also planned for this Health Canada licensing submission (http://ibn.fm/beQXS).

Organigram Holdings Inc. is a Nasdaq Global Select and Toronto Stock Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada, and it ships to all 10 Canadian provinces, establishing a growing coast-to-coast network. The company is certified by Ecocert Canada to produce organically grown medicinal cannabis. A portion of the cannabis currently produced in the facility is organically grown, and a portion is mineral grown.

The company is also committed to developing international business partnerships to extend its global footprint. In addition, Organigram has developed a portfolio of legal, adult-use recreational cannabis brands, including the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick.

For more information, visit the company’s website at www.Investors.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• SPRWF released impressive numbers in its latest financial report
• The company highlighted its stable position in a roller-coaster industry
• The 7ACRES brand plays a key role in the company’s current and future growth initiatives

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is ending its FY2019 as one of the few Canadian cannabis businesses building sustainable operations and valuable brands, according to the company’s FY2019 year-end report (http://ibn.fm/UworA). The report announced impressive numbers that indicate the company’s stable position in a sector that has been rocked by up-and-down performance throughout the year.

The company released its Q4 2019 and year-end financial results, noting the following:

• Total revenue for FY2019 was $41.8 million, a 370 percent increase from FY2018, which totaled $8.9 million;
• The company achieved its first positive adjusted EBITDA quarter of $3.2 million;
• Q4 2019 net revenue totaled $19 million, a 90 percent increase from Q3 2019, which reached $10 million; and
• Net revenue for fiscal 2020 is forecast to be between $150 million and $180 million, with positive adjusted EBITDA expected for fiscal 2020.

The company pointed to its core recreational flower brand, 7ACRES, as key to its impressive revenue performance. Committed to providing enthusiasts with hand-crafted cannabis flower that delivers an uncompromised experience, revenue from 7ACRES grew 443 percent year-over-year, from $3.5 million in Q4 2018 to $19 million in Q4 2019, and 90 percent quarter-over-quarter, from $10 million in Q3 2019.

“Our positive adjusted EBITDA and significant revenue growth in the fourth quarter reflects the rapid scale of our 7ACRES business and continued strong sales pricing for our brands from the provinces as we transition our premium supply to recreational sales channels,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release.

As 7ACRES focused on transitioning sales from its legacy wholesale contracts to recreational sales channels, the brand’s revenue from recreational markets increased by 51 percent between Q3 2019 and Q4 2019. In addition, 7ACRES continues to build equity among consumers, with the promise of new product forms and introduction of new proprietary strains like Jack Haze.

Jack Haze is the first sativa-dominant strain to enter the market under the 7ACRES brand and one of the few sativa-dominant strains available in Canada (http://ibn.fm/OSze3). With its novel traits and differentiated profile, Jack Haze is securing premium pricing in the provinces where it is available.

Supreme Cannabis CEO, Navdeep Dhaliwal concluded his remarks by commenting on some key growth drivers for the company.

“We began fiscal 2020 with two accretive acquisitions that expanded our addressable markets and provided valuable licensed operating assets and focused expertise,” Dhaliwal continued. “As we integrate these businesses and realize further efficiencies from our scaled 7ACRES operations, we expect all of our brands to meaningfully contribute to the revenue we have forecasted for fiscal 2020. Amidst the noise of this new marketplace, Supreme Cannabis has taken a strategic and disciplined approach to develop a focused business with clear pillars: best-in-class infrastructure, top consumer brands, advanced intellectual property, and high-impact and capital-light exposure to developing international markets.”

Supreme Cannabis’ portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco Cannabis Corp., a wellness cannabis brand and a multi-licensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, an cannabis oil producer located in southern Africa; Supreme Heights, an investment platform focused on CBD brands in the UK and Europe; and a brand partnership and licensing deal with Khalifa Kush Canada ULC.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Xalles Holdings is a payment auditing services company building a fintech transaction support strategy through acquisitions and mentoring
• The company’s subsidiaries offer services including program management, marketing capabilities, investment and financial management
• Xalles recently reported its fifth consecutive quarter of revenue generation

The financial transaction systems that support all business enterprises have changed throughout the course of history, but what has never changed is the common goal of securing a means by which creators, regardless of their product class, can profit by providing someone else those products and services, and also by which consumers can acquire products or services by giving up an acceptable measure of asset to obtain them.

Xalles Holdings Inc. (OTC: XALL) has established its mission of supporting investment, financing and commerce systems in order to ensure that these financial transactions can take place unhindered by the multitude of challenges that the modern marketplace may pose – challenges that may include technological processing issues, language and cultural connections, security confidence or resource management efficiencies.

Modern mobile technology has made the marketplace an ever-growing field of dreams by effectively reducing the divisions and temporal distances involved in global commerce. As fintech systems bolstered by the blockchain have arisen as alternatives to the traditional government-secured institution banking model, companies such as Xalles Holdings have developed strategies for keeping the technological highways humming with trade.

Xalles Holdings is working to become the dominant provider of payment systems by acquiring and mentoring select fintech firms with developing revenue streams and opportunities to boost those revenues. The company’s subsidiaries provide or are preparing to provide investment management capabilities, post-payment auditing using a proprietary software platform, payment card financial services and rewards programs that include non-profit fundraising platforms, among other things.

“The common element… is that every project or company we acquire has a business model that ultimately ends up setting up a payment or financial transaction toll gate of one sort or another,” CEO Thomas Nash said during a September NetworkNewsAudio interview (http://ibn.fm/PLyB4). “This could be anything from technology licensing fees, it could be transaction fees, it could be getting a percentage on a revenue share of volume and transactions that are passing through some form of electronic or other brick and mortar commerce transactions.”

Xalles’ acquisition progression model targets four stages of valuations, with strategies adapted to each one. The first two involve businesses with valuations of less than $1 million. The first target stage involves a fintech monitoring and mentoring program through which Xalles provides webinars and quarterly checkups without any investment involved, while the second provides a fintech management program with advisory services and monetary support, plus an option to acquire the business.

The third target stage involves direct management and shared services through subsidiary acquisition as a firm’s valuation exceeds $1 million. As an acquired business’ value exceeds $20 million, it becomes a candidate for being spun out as a separate public company or divestiture supported with external fundraising and governance structure.

Xalles’ previous fintech projects have included working with the U.S. Department of Defense, Mastercard, Citibank and U.S. Bank’s PowerTrack service. Business Insider Intelligence predicts that increasing mobile electronics use will drive e-commerce, reaching 44 percent of the $1.9 trillion e-commerce market forecast for 2024 and 68 percent of the peer-to-peer (P2P) computer networks’ $760 billion forecast (http://ibn.fm/CbqRf).

Xalles recently reported its fifth consecutive revenue-producing quarter and its expectations to continue building revenues as it rolls out new services and its proprietary technology during the coming year (http://ibn.fm/kOiGz).

For more information, visit the company’s website at www.Xalles.com

NOTE TO INVESTORS: The latest news and updates relating to XALL are available in the company’s newsroom at http://ibn.fm/XALL

• Geyser Brands is building on its mission to help people look, feel and do their best through value-added cannabis product solutions
• The company recently closed on its acquisition of established hemp brands manufacturer Solace Management, adding two-dozen wellness products and 57 SKUs to its stable
• The acquisition adds a 7,500-square-foot, GMP-compliant facility to an existing innovation hub and manufacturing subsidiary in Coquitlam, British Columbia
• Solace recently received approval for sales of a new pain-relief roll-on product following issuance of a natural product number from Health Canada
• The global topical pain relief market is forecast to reach $13.28 billion by 2025, achieving a CAGR of 7.4 percent beginning from 2018

Consumer wellness brand cultivator Geyser Brands Inc. (TSX.V: GYSR) is rapidly building its revenue-generating operation thanks to the September completion of acquisition plans for hemp oil product manufacturer Solace Management, a company whose portfolio includes 57 SKUs of consumer wellness goods and pet care products (http://ibn.fm/n15I4).

Solace recently moved into its new 7,500-square-foot GMP (Good Manufacturing Practices)-compliant facility in Coquitlam, British Columbia, which is expected to trigger up to a 10-fold increase in the company’s production capacity now that it has a Natural Health Product site license from Health Canada. Solace also intends to develop and license new products that are either ready for production or in various stages of development, since construction of the facility is now complete (http://ibn.fm/MlxM6).

Geyser and Solace welcomed yet another marketable product to their stable with the receipt of an NPN (Natural Product Number) from Health Canada for their hemp-based pain relief roll-on, which means that the pain-relief product can now be sold as a natural health product through the company’s Apothecary Naturals line (http://ibn.fm/ArWf7). Health Canada made an assessment of the roll-on and found it to be safe, effective and of high quality when it is used as directed.

“Receiving our NPN supports our vision to develop and build brands based on trust and credibility in an emerging but heavily regulated industry,” Geyser Brands Chairman Brad Kersch stated in a news release. “We now have over 15,000 square feet of GMP-rated manufacturing space and our plans are to increase our capacity significantly in preparation for the next growth phase in the cannabis space.”

The company’s Apawthecary Pets line of products has established itself as a leading source for all-natural hemp-based pet treats, with formulations for snacks, salves and oral drops. Animals, like humans, may suffer from the insomnia, digestive difficulties, pain and inflammation that hemp products are designed to relieve. All of Apothecary’s products are made with organic, cold-pressed and unrefined hemp seed oil extract.

Other Apothecary hemp product lines include Apothecary Naturals for skin care and pain relief, WildTails pet foods and treats, and Apothecary Ink, an antibacterial skin care product for new and old tattoos.

Geyser’s technology is built on a proprietary NanoFusion formulation, which is at the heart of its topical, cream, beverage, baked goods, oil and tincture brands. The formulation, known as NanoFusion Technology, provides a biodelivery system that allows hemp and cannabis products to be rapidly absorbed into the bloodstream for maximum effectiveness (http://ibn.fm/CyFak).

Geyser’s newest roll-on product is expected to hit store shelves and be available on a direct-to-consumer basis beginning in October. The global topical pain relief market saw $7.48 billion in sales during 2017, and, with the legalization of CBD products on an expanding scale, analysts such as those with Allied Market Research predict that it will expand exponentially, reaching $13.28 billion by 2025 and growing at a CAGR of 7.4 percent from 2018 to 2025 (http://ibn.fm/gVNdb).

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at  http://ibn.fm/GYSR

• Entrance into the mainstream retail market and changing attitudes toward wellness are forecast to increase the popularity of CBD oil products in the years to come
• Companies that establish their market position now will be primed to benefit from increased recognition in the future; Neutra Corp. is actively working to accomplish this goal
• To achieve vertical integration, Neutra has finalized the acquisition of VIVIS, a renowned CBD brand, and is also looking into the acquisition of companies that have cultivation and production licenses

The popularity of CBD is growing constantly, with market forecasts indicating that the global CBD industry is likely to reach $22 billion by 2022 (http://ibn.fm/Dw34m). One of the main reasons CBD’s popularity has exploded as of late is related to its multiple health benefits, according to clinical research. Various studies carried out over the years indicate that CBD has anti-inflammatory, anti-anxiety and cognitive-boosting qualities.

In addition, CBD has proven to be incredibly versatile. It’s being featured in a much bigger range of products than any other prominent wellness and health ingredient. CBD can be utilized in many different delivery systems. The ingestion delivery system is used to create foods, beverages, candy and snacks. The subdermal delivery system is used for topicals such as ointments, creams, skin care items and balms. From drinks to candy and even CBD-infused tampons, the range of possibilities seems to be limitless.

An additional shift in wellness trends is also contributing to the popularity of CBD applications. The market is seeing a change from excessive focus on workout routines over the past decade to a chill/slow down wellness mentality. This shift could soon contribute to the emergence of wellness centers that incorporate the use of CBD-based products in the overall relaxation experience (http://ibn.fm/EDAsa).

These trends are expected to help the nutraceutical market grow exponentially in the years to come, reaching $578.23 billion by 2025. CBD oil is expected to have a significant impact on that expansion (http://ibn.fm/mSNjP).

Companies like Neutra Corp. (OTCQB: NTRR) are uniquely positioned to take advantage of the industry’s potential and grab a sizable share of this fast-growing market. An early-stage research and development company focusing on cutting-edge technologies in the nutraceutical, food, drug and environmental purification sectors, Neutra Corp. is currently focused on the rapidly growing hemp sector. Committed to promoting vertical integration, Neutra is expanding its ability to cultivate, manufacture and distribute hemp-based CBD products.

The company is taking steps to expand its market reach via strategic acquisitions. On September 10, 2019, Neutra Corp. finalized its previously announced acquisition of VIVIS Corp., a key move that provides the company with invaluable retail market expansion opportunities. Co-founded by Neutra CEO Sydney Jim, VIVIS is a retail brand of CBD health and nutrition products. Its products satisfy the demand for high potency and high-quality hemp-based CBD oil goods. Third-party product certification differentiates the VIVIS range from other products, ensuring brand recognition.

The most efficient CBD ingestion method is a soft gel, which is the reason why VIVIS launched a soft gel supplement first (http://ibn.fm/8gOJJ). This is the easiest way to take an entire dosage of CBD at once, versus spreading it out over time by drinking a 20-ounce beverage or consuming a plate of food.

Thus far in 2019, Neutra has also pursued the acquisition of various companies that hold licenses for the cultivation and processing of hemp. Notably, Neutra entered into a letter of intent to acquire J3 Holdings – a renowned and well-established hemp cultivator. J3 Holdings has land, a warehouse and a cultivation license that could prove to be an invaluable addition to the Neutra Corp. portfolio.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• B2Digital recently launched its B2 Fighting Series (B2FS) Premier Development League
• The company has expanded its portfolio of fighter groups to five with its acquisition of Strike Hard Productions
• CEO Greg P. Bell discussed his vision for the company in an interview with SmallCapVoice

Florida-based B2Digital Inc. (OTC: BTDG) is building a launching pad for mixed martial arts (MMA) champions to enter the big leagues. The platform – B2 Fighting Series (B2FS) – is meant to be the Premier Development League for the mixed martial arts (MMA) marketplace, offering the best minor league fighters an arena to showcase their pluck and prowess to fans, as well as scouts from the big leagues. The development league got going on September 14, 2019, with the 12-fight Colosseum Combat 50 in Kokomo, Indiana, the first of 10 such events planned for the inaugural B2FS Fall Season.

With the launch of B2FS, B2Digital is stepping up its efforts to become a full-service live event sports company. The company has embarked on a “rollup” strategy of purchasing MMA and sports-related companies and parlaying the acquisitions into an integrated league of subsidiary companies operating in the most lucrative sectors of the billion-dollar MMA marketplace. With its recent acquisition of Strike Hard Productions of Alabama, B2Digital now controls five subsidiaries, or ‘fight groups’. Strike Hard Productions has hosted more than 50 LIVE MMA events in Alabama and Mississippi. It joins B2Digital’s B2 Fighting Series network, which includes the HRMMA, Colosseum Combat, United Combat League and Pinnacle Combat fighting companies, as well as MMA news and social media portal Blue Grass MMA. The inclusion of Strike Hard Productions increases to 10 the number of states in which the B2 Fighting Series will be hosting fights (http://ibn.fm/KHdu9).

B2Digital has fought its way to this stage of development, rising phoenix-like from a struggling video-on-demand outfit, as CEO Greg P. Bell explained in a recent SmallCapVoice interview (http://ibn.fm/dcSTF). Bell also talked with SmallCapVoice host Stuart Smith about his background and experience. He is a pioneer in the entertainment and digital media space and has been working in the field for over 30 years.

Bell was one of the initial vice presidents of business development at Qwest Communications and was instrumental in developing Qwest’s digital media company, Slingshot Networks. He later headed Slingshot, running all of its operations, which included the broadcast studio in Staples Center; TV and news productions; live events at the Staples Center; distribution of a national television show by Warner Brothers TV Distribution; and online television productions and web distribution for the NFL, NBA, NHL, AFL, boxing and the Democratic Convention, as well as live music events.

After his stint at Slingshot, Bell founded B3 Development Group, a firm specializing in developing emerging market entertainment and media companies. He later implemented a merger with B3 Development Group subsidiary B2 Networks and the America ONE Television Network and took the reins as CEO of the combined operation. Under his direction, the company, now called ONE Media Corp., went on to launch the new ONE World Sports TV Network in North America on cable and satellite.

For more information, visit the company’s website at www.B2DigitalOTC.com

NOTE TO INVESTORS: The latest news and updates relating to BTDG are available in the company’s newsroom at http://ibn.fm/BTDG

• IONIC Brands’ move to secure DTC eligibility is expected to promote convenience and liquidity for investors while also boosting the company’s ability to attract new investors
• The announcement follows the presentation of the company’s stellar financial results for Q2; over the reporting period IONIC Brands registered a 377 percent year-over-year increase in revenue
• The company has plans to expand into several U.S. states throughout the balance of 2019 and beyond

On September 18, 2019, IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) (FRA: IB3) announced that it has secured eligibility from the Depository Trust Company (DTC) for its shares on the U.S. OTC Markets (http://ibn.fm/vuNFP).

The DTC uses an electronic method of clearing securities, which speeds up the receipt of stocks and cash, accelerates the settlement process for investors and reduces transactional costs. DTC eligibility enables the stock to be traded over a wider selection of brokerage firms, because DTC eligibility is required by many as a measure of compliance.

DTC eligibility enables IONIC Brands to begin trading shares on its domestic market, where brand recognition is high, CEO and Director John Gorst said in a news release. “The ability for investors to electronically transfer between brokerages in the U.S. is significantly more convenient and provides to existing investors the benefit from greater liquidity and execution speeds, while attracting new investors to gain access that may have been previously restricted from investing in IONIC Brands,” Gorst concluded.

The announcement comes during a period of growth for IONIC Brands, a West Coast-based company whose primary focus has been the manufacture of vape products for recreational cannabis users. At the end of August 2019, the company announced a record revenue increase over the second quarter of the year. The revenues for Q2 were higher by 377 percent than those reported in Q2 2018, reaching $3.86 million (http://ibn.fm/unLS8).

The massive sales growth was attributed mainly to an increase in services, packaging and ancillary products to customers, as well as downstream sales. An increase in licensing and equipment rental revenues was also registered.

During the second quarter, the company also completed multiple acquisitions, most notably that of Washington-based Natural Extractions Inc., which is doing business as Zoots Premium Cannabis Infused Edibles. Zoots develops a wide range of premium cannabis edibles that includes hard candies, drops and energy shots, which are available at licensed retailers in Colorado, Illinois, Massachusetts and Washington. The company also acquired a number of cannabis-infused coffee patents and Nevada-based vape pen manufacturer Vegas Valley Growers North.

The acquisitions have enabled IONIC to expand its sphere of operations into other areas of the recreational cannabis consumption market. Over the coming months of 2019, the company plans to further expand operations and make its products available in various U.S. states that have legalized the recreational use of marijuana. To accomplish the expansion, the company will be in contact with existing license holders at various locations of interest.

Established in 2015, IONIC Brands is a national cannabis holding company that focuses on award-winning premium and luxury cannabis brands. Current operations span across Washington, Nevada, Oregon and California. To ensure optimal quality of all products and to meet state pesticide mandate requirements, IONIC has implemented a Certified Clean verification program, as well as a strict individual batch testing program that ensures full transparency of the manufacturing process.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at  http://ibn.fm/IONKF

• The company hosted site visits with analysts from Canada and the United States
• TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America
• The company is dedicated to making life better, both locally and globally

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) uses certified organic, craft growing practices to cultivate high-quality organic medical cannabis. The company consistently holds to the highest levels of excellence as it strives to become the global leader in organic cannabis solutions. Through innovative tech and low-cost power solutions, TGOD is able to provide cost-efficient premium cannabis.

On September 19-20, the company hosted site visits for approximately 25 analysts at its Hamilton and Valleyfield facilities (http://ibn.fm/zgNwW). This marked the first time that TGOD has shared to this extent its Canadian flower production ramp-up, the unveiling of the cannabis 2.0 portfolio and a sampling of noninfused beverage formulations, which were well received. Management also provided an update on the phased facility’s construction completion.

Along with management, TGOD’s growing operations team introduced analysts from Canada and the United States to the company’s cultivation differentiator, proprietary technology and horticultural practices. Analysts walked the grounds of the combined 1,476,000 sq. ft. purpose-built facilities and received updates on the completion of Hamilton’s hybrid greenhouse and Valleyfield’s anticipated first harvest. Total annual production capacity at Hamilton is now 17,500 kilograms; Valleyfield will have approximately 65,000 kilograms of annual run rate capacity turning on in the fourth quarter of 2019 (http://ibn.fm/lBCeO).

“We are doing something no other producer has done before, growing premium certified organic cannabis at scale,” TGOD CEO Brian Athaide stated in a news release (http://ibn.fm/8Mlx8). “By leveraging our proprietary growing methods, purpose-built facilities and industry-leading horticultural team, we are creating a wide economic moat within the premium organic segment… We are extremely proud to showcase the hard work that went into designing and building these state-of-the-art facilities as well as our cannabis 2.0 portfolio.”

TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America. The company’s approach is unique and includes operating cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. Experience gained from previous business ventures has led TGOD to focus on:

• Cultivating organically and at scale;
• Ensuring logistical and infrastructure controls;
• Utilizing strategic partnerships with experts in their fields; and
• Growing its world class CPG senior management team.

TGOD is committed to making life better and nurturing a community that respects a sustainable way of life. This philosophy is at the heart of everything the company does, both on-site and off. Although the company has eyes on esetablishing itself as the global leader in certified organic cannabis, TGOD has not forgotten its roots. The company’s goal is to also create a positive economic impact in local towns and communities across Canada. Following this mission, TGOD produces more than just cannabis. Community Farm, a plot of land within the Hamilton Ancaster Facility Grounds, grows organic food and provides it to local food-donation programs. More than 2,000 pounds of high-quality food has been given to Hamilton food-share programs, a further example that The Green Organic Dutchman is 100 percent committed to ‘Making Life Better’, both at home and around the world.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project
• POAI is positioned on the cutting edge of future cancer treatments
• The company’s AI-driven platforms are improving cancer patient outcomes and setting a new standard in the industry

For years, cancer treatment has involved human beings playing the role of guinea pigs. Oncologists have become quite adept at diagnosing specific types of cancer, but they mostly lack the data to know which drugs will be most effective in fighting patients’ specific cancer types. Patients leave doctors’ offices hopeful but worried, gambling their recovery on the power of the prescription they received. This is the cancer treatment of today. However, the future of cancer treatment could be transformed with the innovative technologies of Predictive Oncology Inc. (NASDAQ: POAI), a company developing highly customizable assessment methods for cancer patients to guide personalized treatments.

As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (“UK100K”) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes. Helomics’ study centers around utilizing this data to continue improving the effectiveness of its artificial intelligence (AI)-based precision oncology models to drive both the individualization of therapy (right drug for the right patient) as well as the discovery of new treatments. Over the long term, Helomics intends to seek approval to use its precision oncology models as part of the NHS for ovarian cancer treatment.

“The promise of precision oncology is therapy tailored to the patient’s own cancer, yet the reality is that while we can identify alterations in the DNA of the patient’s tumor, most of these mutations are not actionable with current drugs,” Dr. Mark Collins, chief innovation officer at Helomics, stated in a news release (http://ibn.fm/SjzNq). “The goal of this project is to combine genomic profiling of the patient tumor and the drug response of the patient from the Genomics England data with Helomics’ unique data set, utilizing the power of machine learning to create a ‘virtual’ model of the tumor.”

Collins described his team’s ability to use Helomics’ model to guide oncologists in selecting appropriate drugs to best treat each patient. Moving forward, the company seeks to partner with pharmaceutical firms to develop the “next generation” of precision therapies using these models.

“We’re delighted to work with Helomics and its precision oncology products to maximize the benefits to patients,” added Genomics England Chief Commercial Officer Joanne Hackett. “Helomics will collaborate with other companies at the forefront of genomics and technology to ensure that we turn research findings into treatments, diagnostic, and benefits for patients as soon as possible.”

As a result of the UK 100,000 Genomes Project, the United Kingdom became the first nation in the world to apply whole-genome sequencing at scale in direct health care, as well as providing access to high-quality, de-identified clinical and genomic data. This data is crucial for improving outcomes for patients and has established a difference between patients who are able to beat their cancers and those who are not.

As a result of its valuable data set and increasingly effective predictive models, Predictive Oncology is on the cutting edge of what could soon be seen as the norm for cancer treatment.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI